Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has ...
BOSTON, MA / ACCESS Newswire / March 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company ...
Researchers at the Francis Crick Institute, the University of Cambridge, Imperial College London, the University of Liverpool, the University of Cape Town and UKHSA have uncovered a link between an ...
A drug used to treat covid-19 appears to be driving the evolution of the SARS-CoV-2 coronavirus, according to an analysis of the 15 million viruses sequenced around the world so far. The analysis ...
An illustration shows a molecule nestled inside a large lumpy green mass. According to researchers' predictions, the antiviral candidate, venetoclax (red and purple), could limit SARS-CoV-2's ability ...
A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of ...
Share on Pinterest Pfizer has released some key results from a recent oral antiviral study. Soumyabrata Roy/NurPhoto via Getty Images The first oral antiviral treatment available for people with COVID ...
(A) A comprehensive analysis of caffeine binding to one of the spike proteins; (B, C) Caffeine interacts with critical amino acids in the SARS-CoV-2 S protein’s receptor-binding domain (RBD), ...
Experimenting on lab-grown mini-brains and mice, researchers have found that SARS-CoV-19 infection can cause ‘zombie’ cells to accumulate, contributing to the brain fog associated with long COVID, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results